Could a headcap at home beat the blues? new trial tests brain zaps for depression
NCT ID NCT06976697
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study tests if a noninvasive, at-home brain stimulation device (tDCS) can safely ease symptoms of major depression. Two hundred adults with depression will use the device themselves at home for 10 weeks, with video check-ins. The goal is to see if this approach reduces depression scores compared to a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
In short, Inclusion Criteria: * 22 - 70 years of age * Diagnosis of Unipolar MDD (DSM-V) * PHQ-9 score of ≥12 AND MADRS score of ≥ 20 at baseline * Antidepressant medication ongoing * If in psychotherapy, have maintained stable psychotherapy * Have access to a smartphone or other device running Android 7.0+ or iPhone Operating System (iOS) 13+ * Be under the care of a psychiatrist or a primary care physician * Allow communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years * Provide the name and contact of at least two adult persons who reside within a 60-minute drive of the patient's residence. * Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study * Be willing and able to comply with all study procedures * Agree to meet all of the inclusion criteria throughout their participation in the study. Otherwise, the subject will be discontinued from the study * Be able to understand, speak, and read English sufficient for the completion of trial assessments Exclusion Criteria: * Current state of mania or psychosis, or have a history of mania or psychosis. * Treatment resistant depression. * Are diagnosed with vitamin or hormonal deficiencies that may mimic mood disorders, as determined by the investigator. * Be currently receiving any other interventional therapy for MDD other than a stable regimen of antidepressants or psychotherapy as defined in the inclusion criteria or have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation. * Have moderate or greater suicidality risk, or an attempt of suicide during lifetime or any previous hospitalization for suicidal behavior. * Diagnosis of sleep apnea with prescribed treatment (unless they are on CPAP treatment and are compliant with treatment) or a diagnosis of insomnia that is unrelated to depression, as determined by the investigator. * Have any structural lesion or any neurocranial defect or any other clinically significant abnormality that might affect safety, study participation, or confound interpretation of study results, as determined by the investigator. * Have any implant in the brain (e.g., DBS) or neurocranium, or any other active implantable medical device anywhere in the body (e.g. pacemaker, insulin pump). * Have a history of epilepsy or seizures. * Have shrapnel or any ferromagnetic material in the head. * Have any disorder that would impair the ability to complete the study questionnaires. * Have been diagnosed with autism spectrum disorder. * Have an alcohol use disorder or substance use disorder (past 12 months). * Have a cognitive impairment (including dementia). * medications that affect cortical excitability, as determined by the investigator. * Have ever taken esketamine / ketamine for treatment of depression. * Are currently admitted or have ever been admitted to a dedicated psychiatric ward for depression for a period of more than 24 hours. * Have ever been diagnosed with obsessive-compulsive disorder (OCD) or bipolar type 1 or 2 disorder. * Be diagnosed with PTSD, agoraphobia, anorexia or bulimia, panic or personality disorder, with active symptoms, based on the investigator's judgment. * Have any history of myocardial infarction, coronary artery bypass graft (CABG), coronary heart failure (CHF), or history of other cardiac issues. * Be currently experiencing or have a history of intractable migraines. * Be a chronic nicotine user. * Be currently pregnant or breastfeeding or planning to become pregnant or breastfeed any time during the study, or lack a medically acceptable method of contraception in females with child-bearing potential. * Be currently incarcerated. * Be participating concurrently in another clinical investigation or have participated in a clinical investigation within the last 90 days or intend to participate in another clinical investigation during the study. * Have a hairstyle or hair type, such as very thick hair or voluminous hairstyle, that would prevent wearing of the treatment cap tightly enough on the head that the electrodes are held close to the scalp.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Curavit Clinical Research (virtual study site)
RECRUITINGBoston, Massachusetts, 02116, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway lift teen depression in primary care?
- Can Anti-Inflammatory drugs lift depression that Won't budge?
- A brain stimulation trial aims to rewire the circuit behind depression
- Can pairing ketamine with talk therapy beat depression alone?
- Genetic matchmaking for antidepressants: a global trial puts personalization to the test
- Could a common vitamin lift depression in young people?